Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07473752 · ClinicalTrials.gov registry record · Phase 1
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TNX-1500 in Healthy Subjects
A Phase 1 study, sponsored by Tonix Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT07473752 is a Phase 1 study that has completed, run by Tonix Pharmaceuticals. The registered enrollment target is 26 participants.
The verdict
NCT07473752, a Phase 1 study, has completed, sponsored by Tonix Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TNX-1500 in Healthy Subjects
Interventions
- DRUG TNX-1500
- DRUG Placebo: USP 0.9% sterile saline for injection
- BIOLOGICAL Keyhole Limpet Hemocyanin (KLH)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2023-07-18 |
| Est. Completion | 2024-02-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07473752
The ClinicalTrials.gov registry entry for NCT07473752 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tonix Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which TNX-1500 is the first listed.
NCT07473752 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07473752 about?
NCT07473752 is a clinical study titled "A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TNX-1500 in Healthy Subjects". A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TNX-1500 in Healthy Subjects
What is the current status of trial NCT07473752?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2023-07-18. Estimated completion is 2024-02-22.
What interventions are being tested in trial NCT07473752?
The interventions under investigation include: TNX-1500 (DRUG), Placebo: USP 0.9% sterile saline for injection (DRUG), Keyhole Limpet Hemocyanin (KLH) (BIOLOGICAL).
Who is sponsoring clinical trial NCT07473752?
This trial is sponsored by Tonix Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.